Anti-Vibrio Compounds Derived from Mangrove Fungus Aspergillus sclerotiorum, Their Preparation Methods and Applications
By extracting and isolating anti-vibrio compounds from the mangrove fungus Aspergillus sclerotiorum, the problems of drug resistance and ecological damage caused by the overuse of anti-vibrio drugs in the prior art have been solved, and a highly efficient inhibitory effect on a variety of Vibrios and a simple preparation method have been provided.
Patent Information
- Application Number
- CN202611197655.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2026-07-16
- Filing Date
- 2026-08-07
- Publication Date
- 2026-11-17
AI Technical Summary
The overuse of existing anti-vibrio drugs has led to the spread of bacterial resistance and damage to aquatic ecosystems. There is a lack of systematic screening and research, and there is an urgent need to develop safe and effective natural anti-vibrio agents.
Anti-Vibrio compounds were extracted and isolated from the mangrove fungus Aspergillus sclerotiorum, and the compounds were prepared through specific steps of fermentation, extraction and chromatography for application as drugs against Vibrio diseases in aquaculture.
The compound exhibits significant inhibitory effects against various Vibrio species, particularly showing high activity against Vibrio parahaemolyticus. The extraction method is simple and feasible, and its market application prospects are promising.
Smart Images

Figure CN123100623A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of microbial technology, and in particular to a mangrove fungus. Aspergillus sclerotia Anti-vibrio compounds from which they are derived, their preparation methods, and their applications. Background Technology
[0002] Vibrio species are typical Gram-negative pathogens in marine and estuarine environments. They can infect humans through contact with seafood and seawater, causing diseases such as gastroenteritis and septicemia. They are also major pathogens restricting the development of aquaculture. Among them, Vibrio parahaemolyticus-induced acute hepatopancreatic necrosis has caused a significant reduction in shrimp production, resulting in huge economic losses for global aquaculture. Vibrio alginolyticus and Vibrio harveyi also frequently cause aquatic diseases, seriously threatening the healthy development of the aquaculture industry.
[0003] Currently, aquaculture production mainly relies on antibiotics to control vibrio diseases. However, long-term overuse has led to numerous problems such as the spread of bacterial resistance, drug residues, and damage to aquatic ecosystems. The horizontal spread of resistance genes further increases the difficulty of disease control, necessitating the development of safe, efficient, and environmentally friendly novel natural anti-vibrio agents. Marine fungi are a high-quality resource for novel antimicrobial active natural products, and Aspergillus fungi have been proven to produce a variety of anti-vibrio active metabolites.
[0004] The unique habitat of mangroves can induce endophytic fungi to synthesize novel and bioactive secondary metabolites, possessing enormous potential for drug discovery. Current research in this area remains fragmented, lacking a systematic screening and research framework targeting the anti-Vibrio activity of mangrove endophytic fungi. Summary of the Invention
[0005] The purpose of this invention is to address the technical deficiencies in existing technologies by providing a mangrove fungus. Aspergillus sclerotiorum The source of the compounds, their preparation methods, and their application in the preparation of anti-vibrio drugs.
[0006] The technical solution adopted to achieve the purpose of this invention is: The application of a compound in the preparation of an anti-Vibrio drug, wherein the compound has the following structural formula: .
[0007] In the above technical solution, the Vibrio is a Vibrio disease in marine aquaculture, preferably Vibrio erwinii, Vibrio alginolyticus, Vibrio corallolyticus, Vibrio parahaemolyticus, Vibrio schreiberensis, or Vibrio harveyi.
[0008] In the above technical solution, the compound is derived from mangrove fungi. Aspergillus sclerotiorum Its preparation method includes the following steps: Step 1, prepare the seed culture medium, and... Aspergillus sclerotiorumThe strains were inoculated into seed culture medium and cultured to obtain seed culture solution; Step 2: Inoculate the seed culture medium obtained in Step 1 into the fermentation medium and culture to obtain the fermentation product; Step 3: Extract the fermentation product obtained in Step 2 with an equal volume of ethyl acetate 3 to 5 times, combine the extracts and concentrate under reduced pressure to obtain an extract. Step 4: The extract obtained in Step 3 was subjected to reduced pressure normal-phase silica gel column chromatography, using petroleum ether and ethyl acetate in a gradient elution ratio of 100:0 to 0:100 (v / v). The petroleum ether:ethyl acetate eluent was then subjected to medium-pressure reversed-phase silica gel column chromatography, with MeOH and H2O in a v / v ratio of 1:9 as the eluent. This was followed by medium-pressure reversed-phase silica gel column chromatography, with MeOH and H2O in a v / v ratio of 3:7 as the eluent. Finally, the extract was prepared by high-performance liquid chromatography (HPLC) to obtain the above-mentioned compound.
[0009] In the above technical solution, in step 1, the seed culture medium includes 1.5wt%~3.5wt% glucose, 25.0wt%~35.0wt% potato, 0.3wt%~0.8wt% crude sea salt, and the remainder is water. After the seed culture medium is prepared, it is sterilized at 121~140℃ for 25~30 minutes.
[0010] In the above technical solution, in step 1, the culture temperature is 36~38℃ and the culture time is 3~4 days.
[0011] In the above technical solution, in step 2, the mass ratio of rice to sea salt in the fermentation culture medium is 3.5:5 to 4.5:5, and the mass concentration of sea salt is 0.4% w / v to 0.6% w / v; after the fermentation culture medium is prepared, it is sterilized at 121 to 140°C for 25 to 30 minutes.
[0012] In the above technical solution, in step 2, the culture temperature is 26~28℃, the culture is static, and the culture time is 28~30 days.
[0013] In the above technical solution, in step 4, the chromatographic column used in the high-performance liquid chromatography (HPLC) is a Cosmosil C18, model 10×250mm, with a packing particle size of 7. μ m, the flow rate is 2 mL / min, and the mobile phase is MeOH and H2O with a volume ratio of 28:72.
[0014] Another aspect of the invention includes an anti-vibrio drug comprising an anti-vibrio compound or a pharmaceutically acceptable salt of an anti-vibrio compound. A "pharmaceutically acceptable salt" means an addition salt of a non-toxic inorganic or organic acid and / or base, see Salt selection for basic drugs, Int. J. Pharm. (1986), 33, 201–217.
[0015] The structural formula of the anti-Vibrio compound is: .
[0016] In the above technical solution, the anti-vibrio drug also includes excipients.
[0017] In the above technical solution, the anti-vibrio drug is an anti-vibrio disease drug for aquaculture.
[0018] Compared with the prior art, the beneficial effects of the present invention are: 1. All compounds of the present invention can inhibit Vibrio erwinii ( Vibrio owensii ), Vibrio alginolyticus ( Vibrio alginolytic ), Vibrio lysinensis ( Vibrio coralliilyticus Vibrio parahaemolyticus ( vibrissa parahaemolytic ), Vibrio schrei ( Vibrio shilonii ), Vibrio harveyi ( Vibrio harveyi ), especially against Vibrio parahaemolyticus ( parahaemolytic vibrio It has significant activity.
[0019] 2. The compound separation and extraction method of the present invention is convenient and quick, can be widely promoted and applied, and has good market application prospects. Attached Figure Description
[0020] Figure 1 It is a compound 1 H NMR spectrum; Figure 2 It is a compound 13 C NMR spectrum. Detailed Implementation
[0021] The present invention will be further described in detail below with reference to specific embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
[0022] Example 1 A mangrove fungus Aspergillus sclerotiorum A method for preparing anti-Vibrio compounds from this source includes the following steps: Step 1, Aspergillus sclerotiorum Microbial culture: Prepare seed culture medium: 40g glucose, 600g potato, 10g sea salt, 2.0L water, evenly dispensed into 8 1000mL Erlenmeyer flasks, sterilized at 121~140℃ for 25–30 minutes.
[0023] The fungal strain with Genbank login number KC461519 Aspergillus sclerotiorum Inoculate the seed culture medium into the prepared seed culture medium and culture at 36~38℃ for 3 days to obtain the seed culture solution; Step 2, Aspergillus sclerotiorum Fermentation: Prepare the fermentation medium: 50g sea salt, 10L water. Divide the sea salt water into 100 1000mL Erlenmeyer flasks containing 80g of rice each, and incubate at 121~140℃ for 25–30 minutes.
[0024] Take an appropriate amount of the seed culture medium obtained in step 1 and inoculate it into an Erlenmeyer flask containing fermentation medium by streaking. Incubate at 26-28℃ for 30 days.
[0025] Step 3, Extraction and Separation of Compounds The fermentation product obtained in step 2 was extracted three times with an equal volume of ethyl acetate. The extracts were combined, concentrated, and then subjected to reduced-pressure silica gel column chromatography. Elution was performed using a petroleum ether-ethyl acetate gradient from 100:0 to 0:100, with the petroleum ether:ethyl acetate ratio being 1:1. This fraction was then subjected to medium-pressure reversed-phase silica gel column chromatography with MeOH and H2O at a volume ratio of 1:9, followed by another medium-pressure reversed-phase silica gel column chromatography with MeOH and H2O at a volume ratio of 3:7. Finally, the mixture was prepared by high-performance liquid chromatography (HPLC) using a Cosmosil C18 column, 10×250 mm, 7... μ The flow rate was 2 mL / min, and the mobile phase was MeOH and H2O with a volume ratio of 28:72, and the above compound was finally obtained.
[0026] The structural formula of the compound is shown below:
[0027] compound 1 H and 13 C NMR (400 / 100 MHz, DMSO- d 6) The data is shown in Table 1 below.
[0028] Table 1 Determination of the structure of compound 1: 1 ¹H NMR showed one hydroxyl hydrogen signal δH: 7.87 (¹H, br s, 4-OH) in the low-field region; and three olefin hydrogen signals δH. H5.41 (1H, s H-2), 5.30 (1H, s, H-6a), 5.11 (1H, s, H-6b); A single methine hydrogen signal δ is given in the high-field region. H The carbon atom δC is 2.01 (1H, m, H-5); the methoxy hydrogen signal δC is 3.88 (3H, s, H-8); and the methyl hydrogen signal δC is 1.65 (3H, s, H-7). According to 13C NMR, there are 8 carbon signals in the structure: 1 ketone carbonyl carbon signal δC: 179.4 (C, C-1); 4 double bond carbon signals δC: 170.0 (C, C-3), 140.1 (C, C-5), 115.3 (CH, C-6), 89.3 (CH, C-2); 1 quaternary carbon signal δC: 102.4 (C, C-4); 1 methoxy carbon signal δC: 59.9 (CH3, C-8); and 1 methyl carbon signal δC: 17.1 (CH3, C-7). Therefore, the compound is identified as penicillic acid.
[0029] Example 2 Determination of the anti-Vibrio activity of the compounds of this invention: Experimental methods: The activity of the compound against six Vibrio strains was tested, specifically its inhibitory effect on Vibrio erwinii in humans (…). Vibrio owensii ), Vibrio alginolyticus ( Vibrio alginolyticus ), Vibrio lysinensis ( Vibrio corallilytic Vibrio parahaemolyticus ( Vibrio parahaemolyticus ), Vibrio schrei ( Vibrio Shilonian ), Vibrio harveyi ( Vibrio harveyi ).
[0030] The specific method is as follows: The MIC method is used to evaluate the antibacterial activity of the compound. The test compound and the positive control drug (norfloxacin) are dissolved in DMSO to prepare a 1 mg / mL liquid chromatography-mass spectrometry (LC-MS) solution. In a 96-well microtiter plate, 190 mg / mL of solution is added to each well in the first row. μ L dilutes the bacterial suspension, and 100 is added to each of the remaining rows. μ L of diluted bacterial suspension was then added. Subsequently, 10 μL of positive control solution and 10 μL of test sample solution were added to each well in the first row. After thorough mixing with a multichannel pipette, 100 μL of the solution was aspirated from the first row. μ The L mixture was transferred to the second row and then serially diluted 1:1 to the last row, resulting in final sample concentrations of 25, 12.5, 6.25, 3.12, 1.56, 0.78, 0.39, and 0.19, respectively. μg / mL. 96-well plates were incubated at 37°C for 6 hours, with observations every 2 hours. Sufficient bacterial growth in the negative control was used as the cutoff point for recording and determining the MIC value.
[0031] Experimental results showed that the compound exhibited significant inhibitory effects against all six Vibrio strains. Among the tested pathogens, V. parahaemolyticus and V. coralliilyticus It has the highest sensitivity, with a MIC of 6.25. μ g / mL, followed by V . Owens , Vibrio shilonii and Vibrio harveyi It is 12.5 μ g / mL V . alginolytic 25 μ g / mL (Table 2).
[0032] Table 2 shows the MICs of the compounds against six Vibrio species. Example 3 An anti-Vibrio drug comprising the mangrove fungus described in Example 1 Aspergillus sclerotiorum Anti-vibrio compounds of this origin.
[0033] The above description is only a preferred embodiment of the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. The use of a compound in the preparation of an anti-Vibrio drug, characterized in that, The structural formula of the compound is: 。 2. The application as described in claim 1, characterized in that, The Vibrio species mentioned are Vibrio diseases in marine aquaculture, preferably Vibrio erwinii, Vibrio alginolyticus, Vibrio corallolyticus, Vibrio parahaemolyticus, Vibrio schreiberensis, or Vibrio harveyi.
3. The application as described in claim 1, characterized in that, The compound is derived from mangrove fungi. Aspergillus sclerotiorum Its preparation method includes the following steps: Step 1, prepare the seed culture medium, and... Aspergillus sclerotiorum The strains were inoculated into seed culture medium and cultured to obtain seed culture solution; Step 2: Inoculate the seed culture medium obtained in Step 1 into the fermentation medium and culture to obtain the fermentation product; Step 3: Extract the fermentation product obtained in Step 2 with an equal volume of ethyl acetate 3 to 5 times, combine the extracts and concentrate under reduced pressure to obtain an extract. Step 4: The extract obtained in Step 3 was subjected to reduced pressure normal-phase silica gel column chromatography, using petroleum ether and ethyl acetate in a gradient elution ratio of 100:0 to 0:100 (v / v). The petroleum ether:ethyl acetate eluent was then subjected to medium-pressure reversed-phase silica gel column chromatography, with MeOH and H2O in a v / v ratio of 1:9 as the eluent. This was followed by medium-pressure reversed-phase silica gel column chromatography, with MeOH and H2O in a v / v ratio of 3:7 as the eluent. Finally, the extract was prepared by high-performance liquid chromatography (HPLC) to obtain the above-mentioned compound.
4. The application as described in claim 3, characterized in that, In step 1, the seed culture medium includes 1.5wt%~3.5wt% glucose, 25.0wt%~35.0wt% potato, 0.3wt%~0.8wt% crude sea salt, and the remainder is water. After the seed culture medium is prepared, it is sterilized at 121~140℃ for 25~30 minutes.
5. The application as described in claim 3, characterized in that, In step 1, the culture temperature is 36~38℃ and the culture time is 3~4 days.
6. The application as described in claim 3, characterized in that, In step 2, the mass ratio of rice to sea salt in the fermentation medium is 3.5:5 to 4.5:5, and the mass concentration of sea salt is 0.4% w / v to 0.6% w / v. After the fermentation medium is prepared, it is sterilized at 121 to 140°C for 25 to 30 minutes.
7. The application as described in claim 3, characterized in that, In step 2, the culture temperature is 26~28℃, and the culture is carried out in a static environment for 28~30 days.
8. The application as described in claim 3, characterized in that, In step 4, the HPLC column used is a Cosmosil C18, model 10×250mm, with a packing particle size of 7. μ m, the flow rate is 2 mL / min, and the mobile phase is MeOH and H2O with a volume ratio of 28:
72.
9. An anti-Vibrio drug, characterized in that, This includes anti-vibrio compounds or pharmaceutically acceptable salts of anti-vibrio compounds, wherein the structural formula of the anti-vibrio compound is: 。 10. The anti-vibrio drug as described in claim 9, characterized in that, The anti-vibrio drug is an anti-vibrio disease drug for aquaculture.
